本文已被:浏览 546次 下载 274次
Received:August 31, 2026 Published Online:October 23, 2026
Received:August 31, 2026 Published Online:October 23, 2026
中文摘要: 2026年《拯救脓毒症运动国际指南》(SSC 2026)在2021版基础上进行了系统更新,共形成129条声明,其中46条为新增内容。新版指南延续早期识别、及时有效抗感染、感染源控制和器官支持等基本原则,同时对脓毒症筛查、抗菌药物使用、液体复苏、血管活性药物、辅助治疗及长期管理等进行了调整。与具体推荐条目的增减相比,更值得关注的是其临床决策理念的变化:在标准化诊疗框架基础上,更加强调感染可能性、疾病严重程度、动态生理反应及患者个体特征对治疗决策的影响。近年来CLASSIC、CLOVERS、BLING Ⅲ和ANDROMEDA-SHOCK-2等大型随机对照试验,推动了脓毒症治疗由固定流程和统一目标向风险分层、动态评估及个体化干预转变。本文结合SSC 2026的核心更新及近年来重要临床循证研究,重点讨论早期识别与抗感染、血流动力学复苏、辅助治疗和长期管理,并结合我国临床实践,对脓毒症从标准化管理走向精准化治疗的现实基础、临床适用边界和未来研究方向进行思考。
Abstract:The Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026(SSC 2026)represent a full systematic revision based on the 2021 iteration,encompassing 129 consensus statements in total,46 of which are newly added recommendations. While retaining the well-established core tenets of sepsis care,including early identification,timely and appropriate anti-infective administration,infection source control and organ function support,the updated guidelines have introduced targeted revisions across key domains:sepsis screening strategies,antimicrobial stewardship,fluid resuscitation regimens,vasoactive agent dosing,adjunctive interventions and post-sepsis long-term management. Rather than focusing solely on the adjustments to individual recommendations,the most notable paradigm shift embedded in this update lies in its refined clinical decision-making logic. Building on the existing standardized diagnosis and treatment framework,the guidelines explicitly place greater weight on integrating infection pre-test probability,baseline disease severity,real-time dynamic physiological trajectories and individual patient phenotypes into every stage of therapeutic decision-making. Over recent years,landmark large-scale randomized controlled trials including CLASSIC,CLOVERS,BLING Ⅲand ANDROMEDA-SHOCK-2 have continuously fueled the evolution of sepsis management,driving clinical practice away from one-size-fits-all protocols and uniform hemodynamic targets toward risk stratification,iterative dynamic assessment and phenotype-specific individualized interventions. This review contextualizes the core updates of SSC 2026 alongside latest high-level clinical evidence,focusing on four priority domains:early recognition and anti-infective optimization,hemodynamic resuscitation strategies,evidence-based adjunctive therapies and post-sepsis long-term care. Aligned with real-world clinical practice in China,the authors further elaborate on the realistic implementation foundation,clinical applicability boundaries and future research priorities for the ongoing transition of sepsis care from standardized population-based management to precision-guided therapy.
keywords: Sepsis Septic shock Surviving Sepsis Campaign Clinical practice guideline Precision-tailored therapy
文章编号: 中图分类号:R631 文献标志码:A
基金项目:黑龙江省联合基金重点项目(ZL2025H005);哈尔滨医科大学附属第一医院科研创新基金(2024H08);滨湖之光高级医学专家团队项目(BH202401)
引用文本:
